Basic and clinical studies on temafloxacin in urogenital infections

K. Hata, Toyohiko Watanabe, T. Takenaka, S. Uno, T. Hayashi, N. Ono, H. Kumon, H. Ohmori, K. Nanba, K. Kondo, S. Irie, T. Kaneshige

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The penetration into prostatic fluid, antibacterial activity and clinical usefulness of temafloxacin (TMFX), a new quinolone, were studied. 1) The concentrations of TMFX in the prostatic fluid were 0.33, 0.71 and 0.66 μg/ml at 1, 2 and 4 hours after a single administration of 300 mg of TMFX, and the ratios to serum level (prostatic fluid/serum) were 0.32, 0.35 and 0.43, respectively. 2) We determined the MICs of TMFX against clinical isolates (209 strains of 14 species) from urinary tract infections, and compared them with those of ofloxacin (OFLX), ciprofloxacin (CPFX), enoxacin (ENX) and norfloxacin (NFLX). The antibacterial activity of TMFX was inferior to that of CPFX but almost equal to those of other control drugs. 3) The overall clinical efficacy rate, evaluated according to the criteria of the Japanese UTI Committee, was 100% (2/2) in acute uncomplicated cystitis and 69.2% (9/13) in chronic complicated UTI. Bacteriologically, 12 of 14 strains (85.7%) were eradicated. Two patients with chronic prostatitis were evaluated as good and fair by the doctors. 4) No drug-related side effects, including abnormal laboratory findings, were observed in any of the 17 cases.

Original languageEnglish
Pages (from-to)537-546
Number of pages10
JournalChemotherapy
Volume41
Issue numberSUPPL. 5
Publication statusPublished - 1993

Fingerprint

temafloxacin
Infection
Ciprofloxacin
Enoxacin
Norfloxacin
Prostatitis
Ofloxacin
Cystitis
Drug and Narcotic Control
Quinolones
Drug-Related Side Effects and Adverse Reactions
Serum
Urinary Tract Infections
Clinical Studies

ASJC Scopus subject areas

  • Pharmacology

Cite this

Hata, K., Watanabe, T., Takenaka, T., Uno, S., Hayashi, T., Ono, N., ... Kaneshige, T. (1993). Basic and clinical studies on temafloxacin in urogenital infections. Chemotherapy, 41(SUPPL. 5), 537-546.

Basic and clinical studies on temafloxacin in urogenital infections. / Hata, K.; Watanabe, Toyohiko; Takenaka, T.; Uno, S.; Hayashi, T.; Ono, N.; Kumon, H.; Ohmori, H.; Nanba, K.; Kondo, K.; Irie, S.; Kaneshige, T.

In: Chemotherapy, Vol. 41, No. SUPPL. 5, 1993, p. 537-546.

Research output: Contribution to journalArticle

Hata, K, Watanabe, T, Takenaka, T, Uno, S, Hayashi, T, Ono, N, Kumon, H, Ohmori, H, Nanba, K, Kondo, K, Irie, S & Kaneshige, T 1993, 'Basic and clinical studies on temafloxacin in urogenital infections', Chemotherapy, vol. 41, no. SUPPL. 5, pp. 537-546.
Hata K, Watanabe T, Takenaka T, Uno S, Hayashi T, Ono N et al. Basic and clinical studies on temafloxacin in urogenital infections. Chemotherapy. 1993;41(SUPPL. 5):537-546.
Hata, K. ; Watanabe, Toyohiko ; Takenaka, T. ; Uno, S. ; Hayashi, T. ; Ono, N. ; Kumon, H. ; Ohmori, H. ; Nanba, K. ; Kondo, K. ; Irie, S. ; Kaneshige, T. / Basic and clinical studies on temafloxacin in urogenital infections. In: Chemotherapy. 1993 ; Vol. 41, No. SUPPL. 5. pp. 537-546.
@article{70380c36b3b146d381c3ad69021ced5d,
title = "Basic and clinical studies on temafloxacin in urogenital infections",
abstract = "The penetration into prostatic fluid, antibacterial activity and clinical usefulness of temafloxacin (TMFX), a new quinolone, were studied. 1) The concentrations of TMFX in the prostatic fluid were 0.33, 0.71 and 0.66 μg/ml at 1, 2 and 4 hours after a single administration of 300 mg of TMFX, and the ratios to serum level (prostatic fluid/serum) were 0.32, 0.35 and 0.43, respectively. 2) We determined the MICs of TMFX against clinical isolates (209 strains of 14 species) from urinary tract infections, and compared them with those of ofloxacin (OFLX), ciprofloxacin (CPFX), enoxacin (ENX) and norfloxacin (NFLX). The antibacterial activity of TMFX was inferior to that of CPFX but almost equal to those of other control drugs. 3) The overall clinical efficacy rate, evaluated according to the criteria of the Japanese UTI Committee, was 100{\%} (2/2) in acute uncomplicated cystitis and 69.2{\%} (9/13) in chronic complicated UTI. Bacteriologically, 12 of 14 strains (85.7{\%}) were eradicated. Two patients with chronic prostatitis were evaluated as good and fair by the doctors. 4) No drug-related side effects, including abnormal laboratory findings, were observed in any of the 17 cases.",
author = "K. Hata and Toyohiko Watanabe and T. Takenaka and S. Uno and T. Hayashi and N. Ono and H. Kumon and H. Ohmori and K. Nanba and K. Kondo and S. Irie and T. Kaneshige",
year = "1993",
language = "English",
volume = "41",
pages = "537--546",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Basic and clinical studies on temafloxacin in urogenital infections

AU - Hata, K.

AU - Watanabe, Toyohiko

AU - Takenaka, T.

AU - Uno, S.

AU - Hayashi, T.

AU - Ono, N.

AU - Kumon, H.

AU - Ohmori, H.

AU - Nanba, K.

AU - Kondo, K.

AU - Irie, S.

AU - Kaneshige, T.

PY - 1993

Y1 - 1993

N2 - The penetration into prostatic fluid, antibacterial activity and clinical usefulness of temafloxacin (TMFX), a new quinolone, were studied. 1) The concentrations of TMFX in the prostatic fluid were 0.33, 0.71 and 0.66 μg/ml at 1, 2 and 4 hours after a single administration of 300 mg of TMFX, and the ratios to serum level (prostatic fluid/serum) were 0.32, 0.35 and 0.43, respectively. 2) We determined the MICs of TMFX against clinical isolates (209 strains of 14 species) from urinary tract infections, and compared them with those of ofloxacin (OFLX), ciprofloxacin (CPFX), enoxacin (ENX) and norfloxacin (NFLX). The antibacterial activity of TMFX was inferior to that of CPFX but almost equal to those of other control drugs. 3) The overall clinical efficacy rate, evaluated according to the criteria of the Japanese UTI Committee, was 100% (2/2) in acute uncomplicated cystitis and 69.2% (9/13) in chronic complicated UTI. Bacteriologically, 12 of 14 strains (85.7%) were eradicated. Two patients with chronic prostatitis were evaluated as good and fair by the doctors. 4) No drug-related side effects, including abnormal laboratory findings, were observed in any of the 17 cases.

AB - The penetration into prostatic fluid, antibacterial activity and clinical usefulness of temafloxacin (TMFX), a new quinolone, were studied. 1) The concentrations of TMFX in the prostatic fluid were 0.33, 0.71 and 0.66 μg/ml at 1, 2 and 4 hours after a single administration of 300 mg of TMFX, and the ratios to serum level (prostatic fluid/serum) were 0.32, 0.35 and 0.43, respectively. 2) We determined the MICs of TMFX against clinical isolates (209 strains of 14 species) from urinary tract infections, and compared them with those of ofloxacin (OFLX), ciprofloxacin (CPFX), enoxacin (ENX) and norfloxacin (NFLX). The antibacterial activity of TMFX was inferior to that of CPFX but almost equal to those of other control drugs. 3) The overall clinical efficacy rate, evaluated according to the criteria of the Japanese UTI Committee, was 100% (2/2) in acute uncomplicated cystitis and 69.2% (9/13) in chronic complicated UTI. Bacteriologically, 12 of 14 strains (85.7%) were eradicated. Two patients with chronic prostatitis were evaluated as good and fair by the doctors. 4) No drug-related side effects, including abnormal laboratory findings, were observed in any of the 17 cases.

UR - http://www.scopus.com/inward/record.url?scp=0027742402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027742402&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027742402

VL - 41

SP - 537

EP - 546

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - SUPPL. 5

ER -